| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.10. | BioMarin and Profluent partner on AI-designed enzyme therapies | ||
| 30.09. | Atossa plans shareholder stake in potential PRV proceeds | ||
| 30.09. | OBIO marks $704m funding milestone for Canadian health tech ventures | ||
| 30.09. | Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab | ||
| 29.09. | Novo outlays $2.6bn in Hengrui deal to bolster oral obesity pipeline | ||
| 29.09. | MSD bets $2.13bn on SciBrunch's KRAS (ON) inhibitor | ||
| 29.09. | AstraZeneca to invest $2bn in Summit for ADC combination therapies | ||
| 29.09. | Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma | ||
| 28.09. | AbbVie lands FDA approval for next-generation Parkinson's drug, Juvmo | ||
| 28.09. | Novo inks $1.33bn long-lasting injectable pact with Sweden-based Nanexa | ||
| 28.09. | Daiichi Sankyo, MSD withdraw cancer drug application | ||
| 28.09. | Mirum and Incyte's Atebrioz approved for FOP in US | ||
| 25.09. | Aptar Pharma and Macquarie University partner on drug delivery project | ||
| 25.09. | FDA commissioner nominee affirms MMR vaccine safety despite Trump's claims | ||
| 25.09. | Roche and Earendil forge $1.5bn bispecific discovery deal | ||
| 25.09. | Amberstone and Henlius agree to develop solid-tumour T-cell engagers | ||
| 25.09. | FDA approves Lilly's Onswik for type 2 diabetes in adults | ||
| 24.09. | Eli Lilly outlays $3.35bn for secretive drug discovery pact with China's InnoCare | ||
| 24.09. | Australia starts investigation into OpenAI Medicare breach | ||
| 24.09. | Enveda nabs $311m to progress nature-derived drug pipeline | ||
| 24.09. | Genialis and Inventia to enhance pancreatic cancer treatment testing | ||
| 24.09. | Basecamp Research secures $140m for AI-driven therapies | ||
| 23.09. | European big pharma unites amid 'ringing alarm bells' of continent's dominance | ||
| 23.09. | Boehringer and Envisagenics to develop precision cancer therapies in $1bn deal | ||
| 23.09. | BoomRay and Novartis Pharma sign $900m deal for radioligand therapy |